Valuation: DaShenLin Pharmaceutical Group Co., Ltd.

Market Cap 21.47B 3.18B 2.76B 2.57B 2.36B 4.46B 303B 4.53B 30.31B 11.9B 151B 11.94B 11.67B 506B P/E 2026 *
14.5x
P/E 2027 * 12.5x
Enterprise Value 17.95B 2.66B 2.31B 2.15B 1.97B 3.73B 254B 3.79B 25.34B 9.95B 126B 9.98B 9.76B 423B EV / Sales 2026 *
0.6x
EV / Sales 2027 * 0.53x
Free-Float
34.77%
Yield 2026 *
4.78%
Yield 2027 * 5.27%
Apr. 24 Dashenlin Pharma's Q1 Profit Rises 11% MT
Apr. 24 Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4% MT
Apr. 23 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 23 Dashenlin pharmaceutical 2025 net profit up 35.0% y/y RE
Apr. 22 Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million MT
Apr. 22 DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million. CI
25-10-29 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-10-15 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-09-19 Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024. CI
24-09-17 DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million. CI
1 day-1.46%
1 week+0.86%
Current month+25.42%
1 month+25.42%
3 months+0.69%
6 months-5.75%
Current year+6.98%
1 week 18.14
Extreme 18.14
19.65
1 month 15.8
Extreme 15.8
19.96
Current year 14.39
Extreme 14.39
21.78
1 year 14.39
Extreme 14.39
21.78
3 years 11.92
Extreme 11.92
30.22
5 years 11.92
Extreme 11.92
39.47
10 years 11
Extreme 11.0028
61.63
Manager TitleAgeSince
Chief Executive Officer 44 2019-02-27
Director of Finance/CFO 44 2018-05-09
Human Resources Officer 48 -
Director TitleAgeSince
Chairman 59 2013-07-15
Director/Board Member 63 2016-08-07
Chairman 48 2015-05-27
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%+0.86%+6.02%-32.82% 3.22B
+0.31%+5.07%-21.59%-30.63% 15.97B
+1.70%+4.66%-27.62%-35.55% 7.28B
-3.92%+3.75%-18.58%-7.29% 6.51B
+0.13%+3.32%-6.15%-29.15% 4.07B
+0.37%+4.28%-22.79%-45.99% 3.29B
+0.46%+3.22%-42.45%-23.15% 3.08B
-1.10%+4.35%-10.92%+4.57% 2.71B
-2.14%-0.41%+92.75% - 2.61B
-5.17%-7.04%-37.12%-41.86% 1.53B
Average -1.03%+3.85%-8.85%-26.88% 5.03B
Weighted average by Cap. -0.51%+5.00%-14.38%-27.15%

Financials

2026 *2027 *
Net sales 29.91B 4.43B 3.85B 3.58B 3.29B 6.21B 423B 6.31B 42.23B 16.57B 210B 16.63B 16.26B 706B 33.03B 4.89B 4.25B 3.96B 3.63B 6.86B 467B 6.97B 46.64B 18.3B 232B 18.37B 17.96B 779B
Net income 1.48B 220M 191M 178M 163M 308M 20.98B 313M 2.1B 823M 10.45B 825M 807M 35.02B 1.71B 254M 221M 205M 189M 356M 24.23B 362M 2.42B 950M 12.06B 953M 932M 40.45B
Net Debt -3.52B -521M -453M -422M -387M -731M -49.73B -742M -4.97B -1.95B -24.76B -1.96B -1.91B -83.02B -4.01B -594M -516M -480M -441M -833M -56.67B -846M -5.66B -2.22B -28.21B -2.23B -2.18B -94.6B
Logo DaShenLin Pharmaceutical Group Co., Ltd.
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company is mainly engaged in the chain retail business of Chinese and Western patent medicines, ginseng and antler tonic medicinal materials and Chinese herbal medicine slices, health products, medical devices and other commodities. The Company is also involved in the production of Chinese herbal medicine slices, ginseng and antler tonic, health products, Chinese and Western patent medicines. The Company's brands include Dong Zi Yun Xuan, Cocoking, Nobe Huale, Dongteng Ejiao, and Fuer. The Company mainly conducts business within domestic market.
Employees
41,141
Date Price Change Volume
26-07-30 CN¥18.85 -1.46% 11,929,410
26-07-30 CN¥19.13 +0.79% 9,903,812
26-07-29 CN¥18.98 +0.74% 9,132,549
26-07-28 CN¥18.84 +1.24% 7,934,359
26-07-27 CN¥18.61 +1.14% 7,105,488
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.85CNY
Average target price
24.70CNY
Spread / Average Target
+31.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 603233 Stock